Healthcare Industry News: Neoprobe
News Release - September 11, 2006
ESTECH Signs Expanded Distribution Agreement With Neoprobe
ESTECH to Distribute Quantix Blood Flow Devices in Europe and U.S.STOCKHOLM, Sweden--(HSMN NewsFeed)--Sept. 11, 2006--At the 5th EACTS (European Association for Cardio-Thoracic Surgery) Meeting, ESTECH, Inc., of San Ramon, CA, announced it has expanded the Distribution Agreement with Neoprobe Corporation (OTCBB:NEOP ) for the Cardiosonix Quantix/OR blood flow measurement system to include Europe in addition to the existing agreement covering the United States.
The Quantix/OR is designed to provide surgeons with quantitative hemodynamic information in coronary artery bypass graft (CABG) and carotid endarterectomy procedures.
"The Cardiosonix Quantix/OR blood flow measurement system has been complementary to our sales efforts in the U.S. providing physicians with an innovative new technology for improving cardiac surgery outcomes," said Ray Bertolero, ESTECH Vice President and co-founder. "The Quantix/OR system is an excellent addition to our current offerings for cardiovascular surgery and provides us with a unique opportunity to expand our product offering for cardiovascular surgery in the European market."
About ESTECH
Headquartered in San Ramon, CA, ESTECH offers tools for least invasive techniques and traditional approaches to the procedures that cardiac surgeons do every day -- coronary artery bypass, valve surgery, atrial ablation and surgical treatment of congestive heart failure.
About Neoprobe
Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe's products are available throughout the world and are supported by a world-wide servicing capability.
Source: ESTECH
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
